01—Abstract
Summary
Summary of the 8-K filed May 6, 2024. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. (NYSE: IFF) reported first quarter 2024 results for the period ended March 31, 2024, with reported net sales of $2.90 billiona, a decrease of 4% versus the prior-year period.
On a comparable basis, currency neutral sales increased 5%, led by growth in Scent, Health & Biosciences and Nourish, and volume grew mid-single digits. Reported income before taxes was $115 millionb and reported diluted EPS was $0.23. Adjusted operating EBITDA was $578 million, which the company states improved 20% on a comparable basis, and adjusted EPS excluding amortization was $1.13 per diluted share.
Cash flows from operations were $99 millionc and free cash flow was $(19) million. CEO Erik Fyrwald said the company started the year well and now expects full-year 2024 results to trend towards the higher end of previously announced guidance ranges for sales of $10.8 billion to $11.1 billion and adjusted operating EBITDA of $1.9 billion to $2.1 billion. The company also expects volume toward the higher end of its 0% to 3% range and pricing to increase approximately 1%, versus a previous decline of approximately 2.5%.
Foreign exchange is now expected to have a 3%d to 4% adverse impact on sales growth, versus 0 to 1% previously. Management highlighted portfolio optimization steps, including an agreement to sell the Pharma Solutions business and completion of the Cosmetic Ingredients divestiture, along with a rightsizing of the dividend earlier in the year.
Management described these as steps toward strengthening the capital structure and improving the debt leverage ratio. At quarter end, net debt to credit adjusted EBITDA was 4.4x and total debt was $10.32 billion.
02—Key points
Key Highlights
- Reported net sales of $2.90 billion, down 4% versus the prior-year period; currency neutral sales on a comparable basis rose 5%.
- Reported income before taxes of $115 million and reported diluted EPS of $0.23; adjusted EPS excluding amortization was $1.13.
- Adjusted operating EBITDA of $578 million, with a 19.9% adjusted operating EBITDA margin; comparable adjusted operating EBITDA improved 20%.
- Scent segment led growth, with comparable currency neutral sales up 16% and comparable adjusted operating EBITDA up 55%.
- Pharma Solutions sales declined 11% on a comparable currency neutral basis, primarily due to temporary customer destocking.
- Full-year 2024 guidance now trends toward the higher end of sales ($10.8 billion to $11.1 billion) and adjusted operating EBITDA ($1.9 billion to $2.1 billion) ranges; FX adverse impact raised to 3% to 4%.
- Cash flow from operations was $99 million and free cash flow was $(19) million; net debt to credit adjusted EBITDA was 4.4x.
03—Questions
Frequently Asked Questions
How did IFF perform in the first quarter of 2024?
Reported net sales were $2.90 billion, down 4% from the prior year. On a comparable, currency neutral basis, sales rose 5%, with volume growing mid-single digits. Reported diluted EPS was $0.23 and adjusted EPS excluding amortization was $1.13.
What changed in IFF's full-year 2024 outlook?
The company now expects results to trend toward the higher end of its previously announced sales range of $10.8 billion to $11.1 billion and adjusted operating EBITDA range of $1.9 billion to $2.1 billion. Pricing is now expected to increase approximately 1% versus a decline of approximately 2.5%, and the adverse foreign exchange impact on sales growth is now 3% to 4% versus 0 to 1% previously.
Which business segments drove the quarter?
Scent had the strongest performance, with comparable currency neutral sales up 16% and comparable adjusted operating EBITDA up 55%, led by Consumer Fragrance. Health & Biosciences and Nourish also grew on a comparable basis, while Pharma Solutions declined 11% due to temporary customer destocking.
What portfolio actions did IFF take?
IFF reached an agreement to sell its Pharma Solutions business and completed the previously announced divestiture of its Cosmetic Ingredients business. Management also cited the rightsizing of the dividend earlier in the year as part of efforts to strengthen the capital structure and improve the debt leverage ratio.
How is IFF's balance sheet and cash generation?
Cash flows from operations were $99 million and free cash flow was $(19) million for the quarter. Net debt to credit adjusted EBITDA was 4.4x at quarter end, and total debt to trailing twelve months net loss was (4.1)x. Total debt used in the net debt calculation was $10.32 billion.
04—Continue